Boston Scientifics 790M Volume Ranks 112th as Stock Falls Near 52-Week High Amid Leadership Transition and FDA Scrutiny

Boston Scientific (NYSE:BSX) closed on September 4, 2025, with a 0.22% decline to $108.94, trading near its 52-week high. The stock’s $790 million volume ranked 112th in the market. The company announced that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, will retire effective December 1, 2025. Mirviss will remain as a senior advisor through February 2026, receiving prorated compensation. The company has not yet named a successor, leaving the transition details undisclosed.

Despite the leadership change, Boston Scientific reported strong financial performance, with 21% year-over-year revenue growth to $18.5 billion in the past twelve months. Analysts highlighted 17% organic revenue growth and a 23% rise in earnings per share. Price targets from institutions like Truist, RBC, and Bernstein have been raised to $125–$140, driven by robust performance in electrophysiology and the Watchman product line. However, the FDA flagged safety concerns with the ENDOTAK RELIANCE Defibrillation leads, linking them to patient deaths, which could impact investor sentiment.

The stock’s near-term trajectory remains influenced by mixed signals. While financial results and analyst optimism bolster confidence, regulatory risks and leadership transitions introduce uncertainty. The company’s market capitalization of $159 billion reflects its dominant position in the healthcare sector, though investors may monitor the FDA’s actions and any updates on Mirviss’s replacement.

Backtest results indicate that the stock’s recent performance aligns with historical trends of mixed volatility. Over the past year, the stock has shown resilience amid sector-wide challenges, with key earnings beats and product-driven growth offsetting recalls and regulatory scrutiny. The 52-week high suggests sustained investor interest, though short-term fluctuations are likely as the market digests leadership changes and product-related risks.